

117<sup>TH</sup> CONGRESS  
2<sup>D</sup> SESSION

# H. R. 7640

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as “orphan drugs”).

---

## IN THE HOUSE OF REPRESENTATIVES

MAY 3, 2022

Mr. BILIRAKIS (for himself and Mr. BUTTERFIELD) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as “orphan drugs”).

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

1 **SECTION 1. REAUTHORIZATION OF GRANTS AND CON-**  
2 **TRACTS FOR DEVELOPMENT OF ORPHAN**  
3 **DRUGS.**

4 Section 5(c) of the Orphan Drug Act (21 U.S.C.  
5 360ee(c)) is amended by striking “2018 through 2022”  
6 and inserting “2023 through 2027”.

○